Overture Life Appoints Former Butterfly Network Executive Matt Combs as Chief Commercial Officer to Lead Scale-up of IVF Automation Technology as Demand Surges Worldwide

PALO ALTO, Calif.--(BUSINESS WIRE)--Overture Life, the leader in automated IVF technology that delivered the first live births in the world from automated fertilization and egg freezing, today announced the appointment of Matthew Combs as Chief Commercial Officer (CCO). Combs joins Overture to drive global expansion amid rising domestic and international demand for IVF automation technology that directly addresses the embryologist shortages worldwide. In the newly created role, Combs will lead the company’s global commercialization as it expands access to technology that automates fertilization and egg freezing processes previously done by hand. These include the ICSI.A, the world’s first robot for automated fertilization, and the DaVitri, for automated, consistent, high-quality vitrification that will expand egg freezing beyond specialized IVF facilities. Combs will focus on scaling Overture Life’s fertility technologies to meet growing clinic demand.

Combs has over 15 years of experience driving rapid revenue growth and scaling organizations across healthcare and medtech, from startups to Fortune 500 companies. He most recently served as Chief Growth Officer at Amalgam, where he led the market expansion of the company’s SaaS products. In 2017, Combs joined Butterfly Network as the first commercial hire when the company was pre-revenue, helping scale operations to over $70 million in annual revenue before the company went public in 2021. During his tenure, he transitioned from leading early-stage business development to serving as VP of Sales for the business, managing the commercial organization through periods of rapid growth. He has also held commercial leadership roles at Boston Scientific, Stryker, and FUJIFILM Sonosite.

“We’re seeing clinics from the US and Europe, to Latin America and Asia asking when they can get our systems,” said Hans Gangeskar, CEO of Overture Life. “Matt’s track record building Butterfly Network into a public company gives us exactly the commercial expertise we need as we move from proving our technology works to scaling it globally. The demand is increasing exponentially as clinics want automation that actually delivers tangible results.”

“What I’ve seen with Overture’s technology reminds me of the early excitement around Butterfly Network, that sense of a solution arriving at exactly the right moment,” said Combs. “IVF has been constrained by manual processes that create barriers to accessibility and inconsistency in performance. Overture’s automation addresses real operational challenges that clinics face every day, from embryologist shortages to the need for affordable and predictable outcomes.”

About Overture Life

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company’s DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture’s backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.